22nd Century Free Cash Flow 2011-2024 | XXII
22nd Century free cash flow from 2011 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| 22nd Century Annual Free Cash Flow |
| 2023 |
-59.36 |
| 2022 |
-54.96 |
| 2021 |
-23.58 |
| 2020 |
-15.67 |
| 2019 |
-14.95 |
| 2018 |
-18.29 |
| 2017 |
-13.23 |
| 2016 |
-10.09 |
| 2015 |
-7.36 |
| 2014 |
-6.16 |
| 2013 |
0.40 |
| 2012 |
-1.76 |
| 2011 |
-3.46 |
| 2010 |
-0.91 |
| 22nd Century Quarterly Free Cash Flow |
| 2024-09-30 |
-10.07 |
| 2024-06-30 |
-7.02 |
| 2024-03-31 |
-2.24 |
| 2023-12-31 |
-59.36 |
| 2023-09-30 |
-53.88 |
| 2023-06-30 |
-39.84 |
| 2023-03-31 |
-19.21 |
| 2022-12-31 |
-54.96 |
| 2022-09-30 |
-35.15 |
| 2022-06-30 |
-20.93 |
| 2022-03-31 |
-8.19 |
| 2021-12-31 |
-23.58 |
| 2021-09-30 |
-18.68 |
| 2021-06-30 |
-12.66 |
| 2021-03-31 |
-4.01 |
| 2020-12-31 |
-15.67 |
| 2020-09-30 |
-12.66 |
| 2020-06-30 |
-11.52 |
| 2020-03-31 |
-4.67 |
| 2019-12-31 |
-14.95 |
| 2019-09-30 |
-12.03 |
| 2019-06-30 |
-8.98 |
| 2019-03-31 |
-4.64 |
| 2018-12-31 |
-18.29 |
| 2018-09-30 |
-12.93 |
| 2018-06-30 |
-8.69 |
| 2018-03-31 |
-3.32 |
| 2017-12-31 |
-13.23 |
| 2017-09-30 |
-10.51 |
| 2017-06-30 |
-7.07 |
| 2017-03-31 |
-2.71 |
| 2016-12-31 |
-10.09 |
| 2016-09-30 |
-8.11 |
| 2016-06-30 |
-5.91 |
| 2016-03-31 |
-2.80 |
| 2015-12-31 |
-7.36 |
| 2015-09-30 |
-4.89 |
| 2015-06-30 |
-3.61 |
| 2015-03-31 |
-2.52 |
| 2014-12-31 |
-6.16 |
| 2014-09-30 |
-3.34 |
| 2014-06-30 |
-1.73 |
| 2014-03-31 |
-0.54 |
| 2013-12-31 |
0.40 |
| 2013-09-30 |
-2.45 |
| 2013-06-30 |
-1.52 |
| 2013-03-31 |
-1.15 |
| 2012-12-31 |
-1.76 |
| 2012-09-30 |
-1.30 |
| 2012-06-30 |
-1.03 |
| 2012-03-31 |
-0.28 |
| 2011-12-31 |
-3.46 |
| 2011-09-30 |
-2.48 |
| 2011-06-30 |
-2.30 |
| 2011-03-31 |
-1.66 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.005B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
